Print
Email
Print Edition StoriesMonday, September 28, 2009
Menino lures biotechs Ginkgo BioWorks, Eutropics to Boston
By Mass High Tech staff
MHT's Julie Donnelly: Life science startups finding investments
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
Mayor Tom Menino touted today the arrival of Ginkgo BioWorks and Eutropics Pharmaceuticals, two biotechnology firms lured to the Boston area with assistance from the city’s LifeTech initiative.
The initiative, created in 2004, aims to attract life sciences firms to Boston by assisting with low-interest loans, site location and permitting. The Boston Redevelopment Authority manages the initiative.
Ginkgo BioWorks received a $150,000 LifeTech Innovation Fund loan from the Boston Local Development Corp. The synthetic biology firm was developed by five MIT researchers and has its 3,400-square foot laboratory located in the Marine Industrial Park on the South Boston Waterfront.
Blood cancer treatment firm Eutropics moved from Woburn to a 1,500-square-foot site at BioSquare, the Boston University Medical Campus in Boston, where it plans to add new employees to its current five-person team, according to a press release. The company was launched out of Harvard Medical School, Dana Farber Cancer Institute and MIT. Eutropics develops new cancer treatment drugs aimed at non-responsive tumors.
In July of 2006, Mayor Menino announced a plan to have 10,000 biotech-related jobs in place by the year 2010.
Mass High Tech last reported on new biotechnology firms brought to Boston through the LifeTech iniative in 2008. The companies at that time included Soadco SL, Paratek Pharmaceuticals Inc. and Cogito Health Inc.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
